COMPANY:

Tethis

"Tethis S.p.A., a pioneer in standardized liquid biopsy platform development, and Sheba Medical Center, Israel’s largest medical center consistently ranked as a Top 10 World’s Best Hospital by Newsweek magazine, today announced a research collaboration to evaluate circulating tumor cells (CTCs) in rectal cancer patients using Tethis’ proprietary technology. Under the agreement, a Tethis’ See.d®instrument will be installed at Sheba’s Institute of Pathology. "

"Tethis S.p.A...announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and will measure the number and kind of tumor cells (cellular residual disease) and DNA (molecular residual disease) released from the tumor in the blood."

"Tethis S.p.A...is pleased to announce the enrollment of the first two patients in the clinical study TET-22-001. This study, titled 'Feasibility evaluation of See.d pre-analytical platform performance: from whole blood to plasma and SmartBioSurface® slides for liquid biopsy applications', is being conducted at the European Institute of Oncology in Milan, Italy."